Sarcopenia Treatment Market to Reach $4.69 Billion by 2029, Growing at a CAGR of 6%

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Sarcopenia Treatment Industry Expected To Reach By 2029, Starting From 2025 Levels?

The sarcopenia treatment market has experienced substantial growth in recent years. Its valuation is anticipated to increase from $3.52 billion in 2024 to $3.72 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.8%. The market’s historical expansion can be attributed to an aging population, improved awareness and diagnosis, evolving lifestyle changes, public health initiatives, and regulatory approvals.

Significant expansion is anticipated for the sarcopenia treatment market over the upcoming years. By 2029, its valuation is projected to reach $4.69 billion, demonstrating a compound annual growth rate (CAGR) of 6.0%. This growth during the forecast period is largely driven by factors such as personalized medicine, nutritional interventions, digital health platforms, efforts in patient education and empowerment, and global health initiatives. Key trends expected during this period encompass personalized therapies, the emergence of novel drug classes, the integration of digital health, collaborative research initiatives, and continued investment in research and development.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13926&type=smp

Which Drivers Are Supporting Growth Of The Sarcopenia Treatment Market?

An anticipated increase in malnutrition is projected to fuel the expansion of the sarcopenia treatment market in the future. Malnutrition encompasses insufficient, excessive, or disproportionate consumption of energy and nutrients, manifesting as undernutrition, as well as overweight, obesity, and diet-linked noncommunicable diseases. Sarcopenia treatment addresses the simultaneous presence of malnutrition and sarcopenia, particularly among older individuals, utilizing strategies like nutritional therapy and exercise to enhance muscle mass, strength, and overall nutritional well-being. As an illustration, a report released in December 2023 by the World Health Organization (WHO), a Switzerland-based United Nations (UN) organization, highlighted malnutrition as a major worldwide health issue, reporting approximately 462 million underweight individuals and 149 million children under 5 experiencing stunting in 2022. Consequently, the increasing prevalence of malnutrition is stimulating the growth of the sarcopenia treatment market.

What Are The Major Segment Categories Driving The Sarcopenia Treatment Market Growth?

The sarcopenia treatmentmarket covered in this report is segmented –

1) By Treatment Type: Protein Supplements; Vitamin B12 Supplements; Vitamin D And Calcium Supplements; Other Treatment Types

2) By Type: Primary Sarcopenia; Secondary Sarcopenia

3) By Route Of Administration: Oral; Parenteral; Enteral

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels

Subsegments:

1) By Protein Supplements: Whey Protein; Casein Protein; Soy Protein; Plant-Based Protein

2) By Vitamin B12 Supplements: Cyanocobalamin; Methylcobalamin

3) By Vitamin D And Calcium Supplements: Vitamin D2; Vitamin D3; Calcium Carbonate; Calcium Citrate

4) By Other Treatment Types: Exercise Programs; Hormone Replacement Therapy; Other Nutritional Interventions

What Are The Latest Industry Trends Transforming The Sarcopenia Treatment Market?

Leading companies within the sarcopenia treatment market are intensifying their efforts to develop numerous advanced clinical study options, aiming to provide improved treatment choices. A clinical study, by definition, involves a systematic investigation on human participants to assess a medical intervention’s safety, effectiveness, or overall outcomes. As an illustration, in September 2023, Biophytis, a biotechnology firm based in France, declared that the Food and Drug Administration (FDA) had authorized the commencement of its SARA-31 Phase 3 study for sarcopenia. This particular study is designed to assess both the efficacy and safety of Sarconeos (BIO101) when used to treat sarcopenic individuals facing a risk of motor disability. It represents a notable leap forward in technological and pharmaceutical treatment strategies, potentially offering significant efficacy and safety advantages for those severely affected by sarcopenia. This marks the first Phase 3 study ever conducted for sarcopenia, having successfully secured FDA authorization. Approximately 900 patients, all over 65 years old and diagnosed with sarcopenia, low walking speed, and diminished hand grip strength, are slated for inclusion in the study. Its primary objective involves evaluating the risk of major mobility disability (MMD), alongside measuring walking speed, hand grip strength, and the patients’ self-reported quality of life.

Who Are The Top Performing Companies In The Sarcopenia Treatment Market In Recent Years?

Major companies operating in the sarcopenia treatment market report are Pfizer Inc., F-Hoffmann La-Roche, Merck Sharp & Dohme Corp. (Merck & Co.), AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories Inc., GlaxoSmithKline plc, Eli Lilly and Company, BASF SE, Nestle Health Science, Haleon Group of Companies, Regeneron Pharmaceuticals Inc., DSM, American Way (Amway) Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Ion Labs Inc., Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt. Ltd., Nutrafill

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Sarcopenia Treatment Market?

North America was the largest region in the sarcopenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Sarcopenia Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13926&type=smp

Browse Through More Reports Similar to the Global Sarcopenia Treatment Market 2025, By The Business Research Company

Reversible Airway Diseases Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/reversible-airway-diseases-treatment-global-market-report

Urothelial Carcinoma Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

Mineral And Bone Disorder Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795